Opdualag 240 mg/80 mg concentrate for solution for infusion
Sponsors
Replimune Inc., iOnctura SA, Stichting Amsterdam UMC, Immatics US Inc.
Conditions
Advanced MelanomaAdvanced Metastatic Ocular/Uveal MelanomaCancer (all types)cutaneous malignantmelanoma
Phase 2
Immune-Related Rheumatological and neurological Adverse Events study (IRRAE study)
RecruitingCTIS2024-516631-27-00
Start: 2023-05-05Target: 495Updated: 2026-01-22
A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib (IOA-244) in Patients with Advanced/Metastatic Ocular/Uveal Melanoma
RecruitingCTIS2024-514333-37-00
Start: 2025-02-25Target: 43Updated: 2025-10-23
Phase 3
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
RecruitingCTIS2024-517062-42-00
Start: 2025-05-02Target: 84Updated: 2025-12-18
A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician’s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3]
RecruitingCTIS2023-508612-29-00
Start: 2025-11-07Target: 193Updated: 2025-11-04